Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

ward-looking statements can be identified by the use of forward-looking terminology such as "expect," "plans," "anticipates," "will," "expects," "goal" or similar expressions, or by express or implied statements with respect to the company's clinical development programs or commercialization activities in HIV or hepatitis C, or any potential pipeline candidates, including any expressed or implied statements regarding the efficacy and safety of IDX184 and any future clinical trials involving IDX184 and expectations with respect to additional milestone payments, future royalty payments, funding of operations and future cash balances. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantees that historical sales of Tyzeka(R)/Sebivo(R) (telbivudine) will in any way suggest future royalty payments or royalty rates owed to the company, or that the company will advance any clinical product candidate or other component of its potential pipeline to the clinic, to the regulatory process or to commercialization. In particular, management's expectations could be affected by unexpected regulatory actions or delays; uncertainties relating to, or unsuccessful results of, clinical trials, including additional data relating to the ongoing clinical trials evaluating its product candidates; the company's ability to obtain additional funding required to conduct its research, development and commercialization activities; the company's dependence on its collaboration with Novartis Pharma AG and GlaxoSmithKline, respectively; changes in the company's business plan or objectives; the ability of the company to attract and retain qualified personnel; competition in general; and the company's ability to obtain, maintain and enforce patent and other intellectual property protecti
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)...  Therapath Neuropathology ( www.Therapath.com ), a leader ... and Military Medical centers both domestically and worldwide.  ... Sweat Gland Nerve Fiber Density (SGNFD) for the ... Demonstration of a reduction in ... skin biopsy is a highly sensitive and specific ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
(Date:7/29/2015)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... announce that the final design specifications of its ... for industrial and regulatory testing will now be ... mark clearance to market the injector in ... (Photo: http://photos.prnewswire.com/prnh/20150729/248373 )  The RCI-02 ...
(Date:7/29/2015)... ... July 29, 2015 , ... Finding gooey or crusty material ... normal. Although there are a considerable number of terms in popular use to describe ... material is a mixture of mucus, blood cells, skin cells and dust, but until ...
Breaking Biology Technology:Neuropathology services for VA and Military health systems 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 2RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 3RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 4RepliCel Life Sciences Unveils Innovative Dermal Injector Prototype 5What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 2What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 3What Are ‘Eye Crusties’ Made Of? uBiome Invites Citizen Scientists to Find Out 4
... (Nasdaq: BMRN ) today announced that Dr. Emil Kakkis, ... 2009. Dr. Kakkis has,decided to leave his position with the ... time to personal endeavors related to rare diseases. Dr.,Kakkis will ... , "I am extremely grateful ...
... Nov. 21 MichBio, the association for,Michigan,s biosciences ... to its fourth annual Expo on Tuesday and ... in Novi, MI. The MichBio Expo is,the ... addition, this year,s event attracted 56 exhibitors. The ...
... Lilly and,Company (NYSE: LLY ) and ImClone Systems ... of the previously announced tender offer,by Lilly,s wholly-owned subsidiary, Alaska ... of $70.00 per share in cash. The,offer expired at ... The depositary for the tender ...
Cached Biology Technology:BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 2BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 3BioMarin Announces the Planned Retirement of Dr. Emil Kakkis, Chief Medical Officer 4MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 2MichBio Expo Draws Nearly 500 Professionals; Career Day Raises Profile 3Lilly Completes Cash Tender Offer for ImClone Systems 2Lilly Completes Cash Tender Offer for ImClone Systems 3
(Date:7/30/2015)... July 30, 2015 Cellecta, Inc., a ... function analysis and biomarker discovery, announced the release ... Library targeting all human protein coding genes. CRISPR ... out" a gene,s function. Cellecta,s new Human Whole ... screening tool so that researchers can investigate in ...
(Date:7/27/2015)... SAN JOSE, Calif. , July 27, 2015 ... leading developer of human interface solutions, today announced ... ClearPad ® touchscreen solution for its stylish ... controller for its proven reliability, low power and ... with a wet finger. Huawei designers also required ...
(Date:7/27/2015)... 2015   Zynx Health ™, the market ... solutions, today announced that its ZynxCarebook ™ ... Android smartphones and tablets. With this expansion, care ... use ZynxCarebook to securely exchange messages and share ... transitions to other care settings, and improve clinical ...
Breaking Biology News(10 mins):CELLECTA, INC. Announces Launch of Human Whole Genome CRISPR Knockout Library 2Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3
... Society (ACS) News Service Weekly PressPac with news from ... credit the individual journal or the American Chemical Society ... ARTICLE #1 FOR IMMEDIATE RELEASE , Hyped-up hopes for ... reporting an advance towards tapping the immense potential of ...
... biomedical researchers from the USC Viterbi School, the College and ... $6-million Bioengineering Research Partnership grant from the National Institutes of ... older adults who suffer from significant vision loss. ... Norberto Grzywacz, professor of biomedical engineering in the Viterbi School ...
... California, Irvine scientists have discovered how to reverse the ... form of mental impairment. Neurobiologist Julie Lauterborn and ... fragile X syndrome blocks brain cells from locking new ... X mental retardation 1 (Fmr1) -- is turned off ...
Cached Biology News:American Chemical Society's Weekly PressPac -- Oct. 3, 2007 2American Chemical Society's Weekly PressPac -- Oct. 3, 2007 3American Chemical Society's Weekly PressPac -- Oct. 3, 2007 4American Chemical Society's Weekly PressPac -- Oct. 3, 2007 5American Chemical Society's Weekly PressPac -- Oct. 3, 2007 6American Chemical Society's Weekly PressPac -- Oct. 3, 2007 7American Chemical Society's Weekly PressPac -- Oct. 3, 2007 8USC biomedical team to participate in $6 million low vision project 2USC biomedical team to participate in $6 million low vision project 3USC biomedical team to participate in $6 million low vision project 4UCI researchers restore memory process in most common form of mental disability 2
... product has been developed to significantly increase ... proteins. Stability is increased at room ... centigrade. This product is subjected to ... or azide. This formulation insures consistently ...
... ThermoStat Plus accurately and conveniently controls the temperature ... maintains different temperature levels up to 99 C*, ... temperatures as low as 5 C. The thermoblocks ... ml tubes, and microplates enable a high degree ...
... developed to significantly increase the shelf life ... is increased at room temperature storage conditions ... product is subjected to 0.2 micron filtration, ... This formulation insures consistently high levels of ...
...
Biology Products: